Express Mail Label No.	Dated:

Docket No.: 05432/000I004-US0

(PATENT)

NOV 1 3 2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Pe Patent Application of: Ken Liljegren, et al.

Application No.: 09/730,380

Customer No.: 07278

Filed: December 5, 2000

Art Unit: 1625

For:

PHARMACEUTICAL COMPOSITION

CONTAINING CITALOPRAM

Examiner: Charanjit AULAKH

## INFORMATION DISCLOSURE STATEMENT (IDS)

MAIL BOX RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application. This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: November 13, 2003

Respectfully submitted,

Jay P. Les

Registration No.: 41,151

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicants



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Patent Contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO		Complete if Kn wn		
			Application Number	09/730,380	
10	VFORMATION		SCLOSURE	Filing Date	December 5, 2000
S	STATEMENT BY APPLICANT			First Named Inventor	Ken Liljegren
				Art Unit	1625
	(Use as many sheets as necessary)		Examiner Name	C. Aulakh	
Sheet	1	of	2	Attorney Docket Number	05432/0001004-US0

	U.S. PATENT DOCUMENTS				
Examiner Cite Name of Patentee or Relevant Passages o		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	US-4,721,723	01-26-1988	Barnes et al.	
	2	US-5,683,720	11-04-1997	Myers et al.	
	3	US-5,840,334	11-24-1998	Raiden et al.	
	4	US-5,869,098	02-09-1999	Misra et al.	
	5	US-5,980,941	11-09-1999	Raiden et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	6	EP-07140663 A3	01-15-1997	Eli Lilly and Company		
	7	GB-2357762	07-04-2001	H Lundbeck A/S		
	8	GB-1358915	07-03-1974	Merck & Co, Inc.		
	9	WO-99/03469	01-28-1999	Smithkline Beecham		
	10	WO-01/68627	09-20-2001	H. Lundbeck A/S	-	
	11	CA-2291072	05-14-1998	H. Lundbeck A/S		
	12	CA-2291129	06-24-1999	H. Lundbeck A/S		
	13	CA-2291067	05-14-1998	H. Lundbeck A/S		
	14	CA-2178637	06-22-1995	Smithkline Beecham		
	15	CA-2291134	04-20-2000	H. Lundbeck A/S		
	16	CA-2163840	05-29-1996	Eli Lilly and Company		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	17	Webpage from Lundbeck website (www.lundbeck.com), company's activites			
	18	Webpage from Lundbeck website (www.lundbeck.com): Product information on Cipramil			
	19	Remington's Pharmaceutical Sciences, 18th Edition, Chapter 89, Oral Solid Dosage Forms, pp. 1633-1658			
	20	Bhogi B. Sheth, et al., Compressed Tablets, Chapter 3 in Pharmaceutical Dosage Forms: Tablets, Vol. 1, H. Lieberman and L. Lachman eds., Marcel Dekker, Inc., New York and Basel, 1979, pp. 109-185			
	21	Chapters 2 to 4 in Pharmaceutical Dosage Forms: Tablets, Vol. 1, H. Lieberman and L. Lachman, eds., Marcel Dekker, Inc. New York and Basel 1989, pp.75-246 (Chapter 2: Tablet			

6	
{W:\054	Date
33/0001	Considered



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
	Substitute for form 1440/05/110			Application Number	09/730,380
INFORMATION DISCLOSURE				Filing Date	December 5, 2000
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Ken Liljegren
				Art Unit	1625
	(Use as many sheets as necessary)			Examiner Name	C. Aulakh
Sheet	2	of	2	Attorney Docket Number	05432/0001004-US0

	and Formulation Design; Chapter 3: Compressed Tablets by Wet Granulation; Chapter 4: Compressed Tablets by Direct Compression)
22	Keith Marshall, "Compression and Consolidation of Powdered Solids, Chapter 4, The Theory and Practise of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds., 3rd Edition, 1986, pp. 66-99
23	Hoener et al., Chapter 4, Factors Influencing Drug Absorption and Drug Availability, Modern Pharmaceutics, 3rd edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1995, pp. 121-153
24	Edward M. Rudnic, et al., Chapter 10, Tablet Dosage Forms, Modern Pharmaceutics, 3d edition, Banker and Rhodes, eds., Marcel dekker, New York and Basel, 1995, pp. 333-394
25	Joseph B. Schwartz, et al., Chapter 18, Optimazation Techniques in Pharmaceutical Formulation and Processing, Modern Pharmaceutics, 3rd Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1995, pp. 727-752
26	Gunsel, et al, Chapter 11, Tablets, The Theory and Practice of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds., 2nd Edition, 1976,pp. 321-358
27	Keith Marshall, Chapter 10, Solid Oral Dosage Forms, Modern Pharmaceutics, 1st Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, p. 359-427
28	Vogel's Textbook of Practical Organic Chemistry, Fourth Edition, pp. 100-263
29	Dr. Fritz Gstirner, Professor fur Pharmazeutische Technologie an der Universitat Bonn, 1973, Einfuhrung in Die Verfahrenstechnik Der Arzneiformung, pp. 201-203
30	O'Connor, R.E. et al., Chapter 91 Powders, Remington: The Science and Practise of Pharmacy, 19th Ed., A. Gennaro, editor, Mack Publishing Co., Easton, 1995, pages 1598-1613
31	Banker, G.S., et al., Chapter 11, Tablets, The Theory and Practice of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds, 3rd Edition, 1986, pgs. 293-345
32	Hoener et al., Chapter 4, Factors Influencing Drug Absorption and Drug Availability, Modern Pharmaceutics, 1st edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, pp. 143-182
33	Joseph B. Schwartz, et al., Chapter 17, Optimazation Techniques in Pharmaceutical Formulation and Processing, Modern Pharmaceutics, 1st Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, pp. 711-734

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\054	Date
32/0001	Considered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.